Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept (RESCUE)
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RESCUE
- 01 Feb 2019 Status changed from recruiting to completed.
- 17 Nov 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015, according to ClinicalTrials.gov record.
- 09 Nov 2013 New trial record